跳至主要内容
临床试验/NL-OMON56688
NL-OMON56688招募中不适用

Gut-brain health effects of PREbiotics in older adults with suspected COgnitive DEcline: the PRECODE study - PRECODE

Wageningen Universiteit0 个研究点目标入组 164 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
164

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Written informed consent
  • 2. Fluency in Dutch (speaking, reading, writing)
  • 3. Age between 60-79 years (at screening)
  • 4. Subjective cognitive decline plus (SCD+), (criteria of Jessen et al. 99):
  • 4.1 Self-reported worsening of memory;
  • 4.2 Indication of repetitive concerns (worries) associated with SCD;
  • 4.3 With at least one of the following two features present:
  • (i) onset of SCD within the last 5 years;
  • (ii) age at onset >=60 years of age;
  • 5. Presence of self-reported risk factors for cognitive decline based on the
  • weighted LIBRA criteria:
  • at least 2 modifiable risk factors need to be present:
  • (i) Diabetes mellitus type II 1 (has your doctor ever told you that you have
  • diabetes yes/no)
  • (ii) High cholesterol 1 (has your doctor ever told you your cholesterol is too
  • high yes/no)
  • (iii) Hypertension 1 (has your doctor ever told you that you have high blood
  • pressure yes/no)
  • (iv) High BMI 1,2
  • (v) Heart disease 1 (has your doctor ever told you that you have a heart or
  • blood vessel condition)
  • (vi) Unhealthy diet 1 (lower regular adherence to Mediterranean diet components
  • such as fish, vegetables, olive oil, pasta
  • and red wine)
  • 1Criteria defined by the short version questions from LIBRA Administration
  • 2 Defined as >=25 kg/m2 for 60-69 years old, and >=28 kg/m2 for >=70 years old,
  • based on self-reported height and weight.

排除标准

  • 1. Current participation in other intervention trials
  • 2.Technologically illiterate (complete incompetence in working with computers,
  • apps, online questionnaires, smartwatches etc.)
  • 3.No internet access from home
  • 4.Clinical diagnosis of >=1 of the following:
  • - Neurological pathology (e.g. MCI, dementia, multiple sclerosis, Parkinson*s
  • disease, epilepsy);
  • - Current malignant disease(s), with or without treatment;
  • - Current psychiatric disorder(s) (e.g. major depressive disorder, bipolar
  • disorder, schizophrenia, psychosis, anxiety, posttraumatic stress disorder);
  • - Symptomatic/decompensated cardiovascular disease (e.g. stroke, angina
  • pectoris, heart failure, recent myocardial infarction);
  • - Severe visual impairment or blindness
  • - Hearing or communicative impairment.
  • - Gastrointestinal tract disorder such as irritable bowel syndrome or
  • inflammatory bowel disease (e.g. Chron*s disease or ulcerative colitis).
  • 5. Current or recent (<6 weeks) use of prebiotic, probiotic, or dietary fibre
  • supplement that may modulate the microbiota, or unwilling to stop the use of
  • supplements during the study
  • 6. Current or recent (<6 weeks) of algae/phytoplankton supplements such as
  • spirulina or chlorella, or unwilling to stop the use of supplements during the
  • 7. Use of psychotropic medication (anti-depressants, anti-psychotics)
  • 8. Use of antibiotics in the 3 months before starting the study or planned use
  • during the study
  • 9. Being an employee of the Human Nutrition and Health Division of Wageningen
  • University.
  • 10. Significant cognitive impairment assessed using the Modified Telephone
  • Interview for Cognitive Status battery (TICS-m score <23)
  • 11. Request to have Apo-E genotype result disclosed
  • 12. Allergy to fish or shellfish
  • 13. Having a contra-indication to MRI scanning including:
  • - Ferromagnetic implants:
  • - Active implantable medical devices such as: insulin pump / medicine pump /
  • neurostimulator; pacemaker / defibrillator;
  • - Other passive implants such as: punctured port-a-cath; synthetic heart valve
  • - Intra-orbital or intra-ocular metallic fragments
  • - Claustrophobia

研究者

相似试验